China's Sichuan Kelun-Biotech Biopharmaceutical (6990.HK) said Thursday night it would license an experimental cancer ...

Pfizer’s VC arm has backed a $100 million series A raise for OTR Therapeutics, as the Chinese biotech tacks on preclinical ...

RA Capital Management’s Peter Kolchinsky says the companies that survived the industry’s 2021 rout are thriving—and looking ...

The companies Cogent Biosciences, Braveheart Bio, and AAVantgarde bagged the biggest biotech funding rounds overall in ...

A Nobel laureate, he identified an enzyme that cuts DNA, laying the groundwork for milestones in scientific research and ...

Legend Biotech (LEGN) announced new long-term clinical and translational data for CARVYKTI from the CARTITUDE-1 and CARTITUDE-4 studies in ...

The partnership will focus on Crescent’s PD-1/VEGF inhibitor CR-001 and Kelun-Biotech’s SKB105, both of which the companies ...

Management has positioned bezuclastinib as a potential alternative to Blueprint Medicines' (BPMT) Ayvakit. This PDGFRα/c-KIT ...

Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus ...

AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Read more here.

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

The George Soros protege has generated legendary returns for decades, so it's hard not to take stock in where Druckenmiller ...